TY - JOUR
T1 - Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
AU - Jindal, Sonali
AU - Pennock, Nathan D.
AU - Sun, Duanchen
AU - Horton, Wesley
AU - Ozaki, Michelle K.
AU - Narasimhan, Jayasri
AU - Bartlett, Alexandra Q.
AU - Weinmann, Sheila
AU - Goss, Paul E.
AU - Borges, Virginia F.
AU - Xia, Zheng
AU - Schedin, Pepper
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes.
AB - Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes.
UR - http://www.scopus.com/inward/record.url?scp=85118580518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118580518&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-26505-3
DO - 10.1038/s41467-021-26505-3
M3 - Article
C2 - 34732713
AN - SCOPUS:85118580518
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 6341
ER -